The U.S. Food and Drug Administration has approved Foundayo (orforglipron), a new once-daily weight-loss pill developed by Eli Lilly, marking a significant expansion in the treatment options available for obesity. The approval, announced on April 1, 2026, positions the drug as a more accessible alternative to the injectable GLP-1 medications that have dominated the weight-loss market over the past two years.
Unlike existing weight-loss injections that require weekly self-administered shots, Foundayo is a pill that can be taken at any time of day, with or without food or water. This convenience factor could make a meaningful difference for patients who have avoided GLP-1 therapy due to a fear of needles or the logistical demands of injectable treatments.
How It Compares
In clinical trials, participants taking the highest dose of orforglipron experienced an average weight loss of 12.4% of their body weight—modestly lower than the 15-21% typically achieved by injectable GLP-1 drugs like Zepbound and Wegovy, but still a clinically significant result. The drug works by mimicking the GLP-1 hormone, which regulates appetite and insulin secretion, helping users feel fuller for longer and reducing overall calorie intake.
Eli Lilly’s entry into the oral weight-loss market puts it in direct competition with Novo Nordisk, which launched its own GLP-1 pill, Wegovy, in December 2025. Both companies have agreed to participate in a White House initiative to make the drugs more affordable, with initial cash prices starting at $149 per month for uninsured patients and Medicare beneficiaries.
Expanding Access to Weight-Loss Treatment
Medical experts say the availability of an oral option could significantly broaden the patient pool. “Fewer than 1 in 10 people who could benefit from a weight-loss medicine are currently taking one,” noted Dr. Catherine Varney, an obesity medicine specialist. Lilly has also indicated plans to pursue additional approvals for the drug, including uses for sleep apnea, hypertension, and stress urinary incontinence. The approval signals a new phase in the commercialization of obesity treatments, with analysts projecting the global weight-loss drug market could exceed $150 billion by the end of the decade.
